Form 4: Verve Therapeutics Director Alexander Cumbo Acquires Stock Options

Alexander Cumbo, a director at Verve Therapeutics, acquired stock options for 136,139 shares of common stock on June 26, 2024.

Summary

• On June 26, 2024, Alexander Cumbo, a director of Verve Therapeutics, Inc., was granted stock options to purchase 136,139 shares of common stock.
• The options were issued under the company's 2021 Stock Incentive Plan as part of the director compensation program.
• The exercise price of the options is $5.02 per share.
• The options vest upon the earlier of the one-year anniversary of the grant date or immediately prior to the first annual meeting of stockholders occurring after the grant date, subject to continued service as a director.
• The options expire on June 25, 2034.

Sentiment

Score: 7

Explanation: The document reflects a routine director compensation practice, which is generally viewed neutrally to positively as it aligns director interests with shareholders.

Positives

• The grant of stock options aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Industry Context

This is a standard practice for compensating board members in publicly traded companies, aligning their interests with shareholders.

Comparison to Industry Standards

• Granting stock options to directors is a common practice in the biotechnology industry.
• Comparable companies like CRISPR Therapeutics and Editas Medicine also use stock options as part of their director compensation packages.
• The vesting schedule and exercise price are typical for such grants.

Stakeholder Impact

• Shareholders may view this positively as it aligns the director's interests with the company's performance.
• Employees are not directly impacted by this transaction.

Key Dates